Kathy Oubre, MS, Chief Operating Officer, Pontchartrain Cancer Center in Covington, Louisiana, shares some barriers to adherence to oral oncolytics that patients may face.
From financial toxicity to lifestyle, there are many factors that could prevent patients from consistently taking their medication. Kathy Oubre, MS, Chief Operating Officer, Pontchartrain Cancer Center in Covington, Louisiana, shares some barriers to adherence to oral oncolytics that patients may face.
There’s no way a checklist can be as comprehensive as it needs to be to cover all possible influential factors, Oubre said. Having a conversation with patients is the best way to get a clear understanding of what their barriers might be and how to overcome them.
Stopping ICIs at 1 or 2 Years May Not Compromise Survival in HNSCC
September 11th 2024This retrospective, population-based study shows strong efficacy across multiple patient subgroups and different lines of therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.